Share This

Public company info - Keymed Biosciences Inc. , 02162.HK
Input the stock code or the company name     Search  
 
 Profile   Information   Data   Financial Ratios   Profit Loss   Cash Flow   Balance   Earnings   Dividend 

Keymed Biosciences Inc., 02162.HK - Cash Flow 2021-12 2020-12 2019-12
Net Cash Flow from Operating Activities -214,637 -119,361 -68,379
Net Cash Flow from Return on Investments & Servicing of Finance 5,964 4,711 1,117
　Interest Received 5,964 4,711 1,117
　Interest Paid 0 0 0
　Dividend Received 0 0 0
　Dividend Paid 0 0 0
　Others 0 0 0
Taxes (Paid) / Refunded 0 0 0
Net Cash Flow from Investing Activities -2,041,843 -117,778 -59,137
　Additions to Fixed Assets -171,786 -19,806 -62,264
　Disposal of Fixed Assets 0 0 0
　Increase in Investments -203,523 -329,500 -257,000
　Decrease in Investments 140,565 385,600 260,165
　Net Cash Flow with Related Parties -41,820 9,386 100,239
　Others -1,765,279 -163,458 -100,277
Net Cash Flow before Financing Activities -2,250,516 -232,428 -126,399
Net Cash Flow from Financing Activities 3,638,376 7,397 505,066
　New Loans 0 0 0
　Loans Repayment -9,684 -5,464 -5,673
　Fixed Income/Debt Instruments 872,111 3,475 410,500
　Repayment of Fixed Income/Debt Instruments -58,154 0 0
　Equity Financing 2,879,144 0 0
　Net Cash Flow with Related Parties -41,820 9,386 100,239
　Others -3,221 0 0
Increase(Decrease) in Cash & Cash Equivalents 1,387,860 -225,031 378,667
Cash & Cash Equivalents at Beginning of Year 199,409 432,608 48,799
Net Cash Flow due to Change in Exchange Rate/Others -66,650 -8,168 5,142
Cash & Cash Equivalents at End of Year 1,520,619 199,409 432,608
Currency Renminbi Renminbi Renminbi
Unit
Auditor's Opinion 1 0 0

Notes:1–Unqualified; 2–Unqualified ( not qualified in respect of fundamental uncertainly because of proper disclosure); 3–Qualified

Mobile | Full
Forum rule | About Us | Contact Info | Terms & Conditions | Privacy Statment | Disclaimer | Site Map
Copyright (C) 2024Suntek Computer Systems Limited. All rights reserved
Disclaimer : In the preparation of this website, 88iv endeavours to offer the most current, correct and clearly expressed information to the public. Nevertheless, inadvertent errors in information and in software may occur. In particular but without limiting anything here, 88iv disclaims any responsibility and accepts no liability (whether in tort, contract or otherwise) for any direct or indirect loss or damage arising from any inaccuracies, omissions or typographical errors that may be contained in this website. 88iv also does not warrant the accuracy, completeness, timeliness or fitness for purpose of the information contained in this website.